期刊簡介 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS LetPub Score 6.1
50 ratings
Rate
Reputation 7.6 Influence 4.8 Speed 7.0 | ||||||||||||||||||||
期刊簡稱 | CRIT REV THER DRUG | ||||||||||||||||||||
ISSN | 0743-4863 | ||||||||||||||||||||
E-ISSN | 2162-660X | ||||||||||||||||||||
h-index | 69 | ||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||
自引率 (2023-2024) | 13.30%自引率趨勢 | ||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||
官方網站 | http://dl.begellhouse.com/journals/3667c4ae6e8fd136.html | ||||||||||||||||||||
在線稿件提交 | http://submission.begellhouse.com/usr/login.html?prod_code=journals | ||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||
出版商 | Begell House Inc. | ||||||||||||||||||||
主題領域 | 医学 | ||||||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||||||
發行頻率 | 隔月刊行 | ||||||||||||||||||||
創刊年 | 1984 | ||||||||||||||||||||
每年文章數 | 17每年文章數趨勢 | ||||||||||||||||||||
黃金OA百分比 | 1.92% | ||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q2
| ||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0743-4863%5BISSN%5D | ||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: >12 Week(s), or Invited contributions | ||||||||||||||||||||
競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS] 的評論 | 撰寫評論 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 20:11:57 評論於 The discussion section is the core part of an SCI paper because it can reflect the breadth and depth of the author's research. Therefore, there is no specified word limit for this section. The length of the discussion section varies depending on the article and the author, with some being several thousand words long and others being tens of thousands of words long(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 15:54:44 評論於 The discussion section is the core part of an SCI paper, as it reflects the breadth and depth of the author's research. Therefore, there is no specific word limit for this section. Depending on the article and the author, the length of the discussion section varies, from a few thousand words to tens of thousands of words(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 破戒阳平 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 23:47:21 評論於 Is the lengthy discussion showcasing the author's reflection on the topic? Does the reviewer have a positive impression of the manuscript?(0) 讚! | 破戒阳平 |
作者: 魂魄彦露 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 14:16:34 評論於 How many words should be included in a typical discussion?(0) 讚! | 魂魄彦露 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-16 21:28:50 評論於 Made a fortune! Published an article last year, and this year it broke 6 points. Dear friends, you also need to have such vision(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2012-11-28 15:24:19 評論於 Can we reach the 3-point line next year? Let's discuss(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us